primarily

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Paribus Embracing DAO transition.

Source Node:
Time Stamp: December 22, 2023 3:10 PM - Modified On: December 22, 2023 - Published By:
Source Cluster:
Republished By Plato

In our journey of developing Paribus, we’ve received a lot of feedback from our community, primarily positive and helpful. But, as is often the case when a small team controls a platform, not everyone agrees with our decisions. At every step, we’ve tried to make the best choices based on the information we had. We’ve always known that, eventually, it would be the community’s turn to take the lead in guiding Paribus. And, as we announced in our recent X-space update, that time is approaching fast with the release of

BitMask Wallet 0.7.0 Soars: A Quantum Leap in Bitcoin Evolution Surges Over 760,000 Wallets in Just One Month

Source Node:
Time Stamp: November 24, 2023 12:02 PM - Modified On: November 24, 2023 - Published By:
Source Cluster:
Republished By Plato

SAN FRANCISCO, November 23, 2023 (ACN Newswire) - DIBA Global, backed by industry titans including Draper Associates, ACTAI Ventures, Waterdrip Capital, Martial Eagle Fund, Brad Mills, Rodney Yesep, and others, has sent shockwaves through the Bitcoin industry with the beta release of BitMask Wallet 0.7.0. This marks a historic moment as the user base surpasses 763,623 wallets. This milestone, achieved without any advertising, underscores the community's trust in DIBA's commitment to advancing Bitcoin utility. Worthy of note is the official partnership between DIBA GLOBAL and Satoshi Lab to foster the development

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

Starbox Group Holdings Ltd. Announces First Half of Fiscal Year 2023 Financial Results

Source Node:
Time Stamp: August 29, 2023 11:37 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Revenue and Net Profit Increased with Technology Driven Services Revenue Accounted for Approximately 43.8% of its Revenue KUALA LUMPUR, Malaysia, August 29, 2023 / Plato / Amplifi. Starbox Group Holdings Ltd. (Nasdaq: STBX) ("Starbox" or "the Company”), a service provider of cash rebates, digital advertising, and payment solutions with a goal of becoming a comprehensive AI solutions provider within Southeast Asia, today announced its unaudited financial results for the six months ended March 31, 2023. Mr. Lee Choon Wooi, Chairman and Chief Executive Officer of Starbox, commented, “We are excited

Dubai Fintech Summit Welcomes Crypto Oasis as Web3 Ecosystem Partner

Source Node:
Time Stamp: May 4, 2023 7:49 AM - Modified On: May 4, 2023 - Published By:
Source Cluster:
Republished By Plato

4th May 2023, Dubai, UAE: Dubai Fintech Summit is proud to announce its partnership with Crypto Oasis as the official Web3 Ecosystem partner for the upcoming summit, which will take place on 8th and 9th May 2023. The Crypto Oasis is a MENA focused Blockchain Ecosystem headquartered in Dubai, UAE. The core elements needed for its growth are Talent, Capital, and Infrastructure. The Ecosystems stakeholders include Investors & Collectors, Start-Ups & Projects, Corporates, Science & Research Institutions, Service Providers and Government Entities & Associations. Crypto Oasis’ vision is to be

Bringing It All Together

Source Node:
Time Stamp: November 30, 2022 1:31 PM - Modified On: November 30, 2022 - Published By:
Source Cluster:
Republished By Plato

It starts with a national brand for music rehearsal space After 15 long years on the road touring with national acts such as Tool, Filter and Rage Against The Machine as lead singer for the Oregon based hard rock band DFiVE9, Nic Yannariello was looking for a way to get off the road, and so in 2003 he built and established the now iconic Hawthorne Theatre, a 600-person concert hall in Portland for national tours and regional acts. Seeing a need for his fellow musicians, Nick then founded Puddletown Studios

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Source Node:
Time Stamp: November 13, 2022 3:46 AM - Modified On: November 17, 2022 - Published By:
Source Cluster:
Republished By Plato

Published: Nov 12th, 2022 | By Mark Terry Verseon Corporation has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform, the companies revealed Tuesday. Adityo Prakash, co-founder and CEO of Verseon and Ed Ratner, CEO at Edammo, discussed the acquisition with BioSpace. “We develop completely new drugs on the computer, atom by atom, then we make them in the laboratory,” Prakash said. "We’re changing how small molecule drugs are designed and developed with a level of efficiency that hasn’t been possible before.” He added that